ClinicalTrials.Veeva

Menu

Evaluation of Paclitaxel Coated Balloon in the Treatment of Dialysis Access Dysfunction

S

Singapore Health Services (SingHealth)

Status

Unknown

Conditions

Kidney Failure
Dialysis Access Malfunction

Treatments

Drug: Paclitaxel Drug Coated Balloon

Study type

Observational

Funder types

Other

Identifiers

NCT04988789
2020/2320

Details and patient eligibility

About

Recent studies of paclitaxel DCB in the treatment of stenosis at dialysis vascular access have shown promising results. Paclitaxel, an anti-proliferation drug, is released during balloon inflation and potentially improve primary patency by slowing down NIH effect. However, meta-analysis have suggested that the use of paclitaxel in lower limbs have increased risk of death in patients. The effect of paclitaxel DCB on dialysis access however remains unknown. Hence, we aim to set up a database to track long-term treatment outcomes of patients treated with Paclitaxel DCB at SGH for their stenosed dialysis access

Enrollment

500 estimated patients

Sex

All

Ages

21 to 99 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • All patients above 21 that is undergoing AVF/AVG fistuloplasty with paclitaxel DCB at SGH is included

Exclusion criteria

  • All patients below 21

Trial contacts and locations

1

Loading...

Central trial contact

Charyl Yap

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems